Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs

The Food and Drug Administration (FDA) approved a new class of anti-diabetic medication (a sodium–glucose co-transporter 2 (SGLT2) inhibitor) in 2013. However, SGLT2 inhibitor drugs are under evaluation due to their associative side effects, such as urinary tract and genital infection, urinary disco...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashraqi, Mutaib M., Chaturvedi, Navaneet, Alam, Qamre, Alshamrani, Saleh, Bahnass, Mosa M., Ahmad, Khurshid, Alqosaibi, Amany I., Alnamshan, Mashael M., Ahmad, Syed Sayeed, Beg, Mirza Masroor Ali, Mishra, Abha, Shaikh, Sibhghatulla, Rizvi, Syed Mohd Danish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866138/
https://www.ncbi.nlm.nih.gov/pubmed/33499241
http://dx.doi.org/10.3390/molecules26030582

Ejemplares similares

Ejemplares similares